144 related articles for article (PubMed ID: 6375853)
1. A phase II trial of teniposide (VM 26) in advanced non-Hodgkin's lymphoma, with emphasis on the treatment of elderly patients.
Tirelli U; Carbone A; Crivellari D; Volpe R; Franchin G; Veronesi A; Galligioni E; Trovò M; Tumolo S; Grigoletto E
Cancer; 1984 Aug; 54(3):393-6. PubMed ID: 6375853
[TBL] [Abstract][Full Text] [Related]
2. VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group Study (EST 1474).
Chiuten DF; Bennett JM; Creech RH; Glick J; Falkson G; Brodovsky HS; Begg CB; Muggia FM; Carbone PP
Cancer Treat Rep; 1979 Jan; 63(1):7-11. PubMed ID: 369693
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of teniposide (VM-26) in multiple myeloma.
Tirelli U; Carbone A; Zagonei V; Brema F; Veronesi A; Grigoletto E; Volpe R
Am J Clin Oncol; 1985 Aug; 8(4):329-31. PubMed ID: 3909805
[TBL] [Abstract][Full Text] [Related]
4. Comparative trial of two teniposide-based combination chemotherapy regimens for the treatment of advanced malignant lymphomas.
O'Connell MJ; Anderson J; Merrill JM; Bennett JM; Glick JH; Berard CW; Neiman RS; Brodovsky HS
Cancer Treat Rep; 1982 Dec; 66(12):2021-5. PubMed ID: 6814757
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the use of teniposide and vincristine in combination chemotherapy for non-Hodgkin's lymphoma.
Cancer Treat Rep; 1982 Jan; 66(1):49-55. PubMed ID: 7053265
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of teniposide in advanced breast cancer.
Boas J; Rasmussen D; Hansen OP; Engelholm SA; Dombernowsky P
Cancer Chemother Pharmacol; 1990; 25(6):463-4. PubMed ID: 2311176
[TBL] [Abstract][Full Text] [Related]
7. [Combination of adriamycin, VM 26, cyclophosphamide and prednisone in the treatment of hematosarcomas].
Laurens A; Thevenot J; Charron D; Jorry F; Dumonchel P; Martola R
Ann Med Interne (Paris); 1977 May; 128(5):493-6. PubMed ID: 334012
[No Abstract] [Full Text] [Related]
8. Treatment of refractory lymphoma with methotrexate, VM-26 (teniposide), procarbazine, and dexamethasone: Cancer and Leukemia Group B study 7902.
Lachant NA; Anderson J; Ginsberg SJ; Cooper MR; Hurd DD; Bloomfield CD; Gottlieb AJ
Med Pediatr Oncol; 1988; 16(6):375-7. PubMed ID: 3264379
[TBL] [Abstract][Full Text] [Related]
9. Non-Hodgkin's lymphomas in the elderly: prospective studies with specifically devised chemotherapy regimens in 66 patients.
Tirelli U; Carbone A; Zagonel V; Veronesi A; Canetta R
Eur J Cancer Clin Oncol; 1987 May; 23(5):535-40. PubMed ID: 3653177
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy for patients with relapsed malignant lymphoma using methyl-GAG and teniposide (VM-26).
Warrell RP; Straus DJ; Young CW
Cancer Treat Rep; 1982 May; 66(5):1121-5. PubMed ID: 7044533
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of teniposide (VM26) in cutaneous T-cell lymphomas.
Sorio R; Tirelli U; Zagonel V; Carbone A; Monfardini S
Am J Clin Oncol; 1990 Feb; 13(1):14-6. PubMed ID: 2305716
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.
Radice PA; Bunn PA; Ihde DC
Cancer Treat Rep; 1979 Aug; 63(8):1231-9. PubMed ID: 225026
[No Abstract] [Full Text] [Related]
13. [Use of preparation VM 26 (epipodophyllotoxin) for treating lymphomas in children and adults].
Kondrat'eva NA; Gershanovich ML; Kondrat'ev VB; Lebedev VN; Vialushkin VIa
Vopr Onkol; 1981; 27(4):82-7. PubMed ID: 7015693
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial.
Rodman JH; Abromowitch M; Sinkule JA; Hayes FA; Rivera GK; Evans WE
J Clin Oncol; 1987 Jul; 5(7):1007-14. PubMed ID: 3598607
[TBL] [Abstract][Full Text] [Related]
15. Treatment of advanced non-Hodgkin's lymphoma with vincristine infusion.
Jackson DV; Paschold EH; Spurr CL; Muss HB; Richards F; Cooper MR; White DR; Stuart JJ; Hopkins JO; Rich R
Cancer; 1984 Jun; 53(12):2601-6. PubMed ID: 6722721
[TBL] [Abstract][Full Text] [Related]
16. [Adriamycin, VM 26, cyclophosphamide and prednisone (AVmCP) combination in the therapy of disseminated lymphoreticulosarcoma (Stages or topographical forms III and IV].
Misset JL; Pouillart P; Amiel JL; Schwarzenberg L; Hayat M; de Vassal F; Musset M; Belpomme D; Jasmin C; Albahary C; Depierre R; Mathé G
Nouv Presse Med; 1975 Dec; 4(44):3117-20. PubMed ID: 768904
[TBL] [Abstract][Full Text] [Related]
17. Unexpected high toxicity in a phase II study of teniposide (VM-26) in elderly patients with untreated small cell lung cancer (SCLC).
Cerny T; Pedrazzini A; Joss RA; Brunner KW
Eur J Cancer Clin Oncol; 1988 Nov; 24(11):1791-4. PubMed ID: 2850194
[TBL] [Abstract][Full Text] [Related]
18. Teniposide (VM-26), an overlooked highly active agent in small-cell lung cancer. Results of a phase II trial in untreated patients.
Bork E; Hansen M; Dombernowsky P; Hansen SW; Pedersen AG; Hansen HH
J Clin Oncol; 1986 Apr; 4(4):524-7. PubMed ID: 3007684
[TBL] [Abstract][Full Text] [Related]
19. Teniposide in recurrent or advanced cervical carcinoma: a phase II trial in patients not previously treated with cytotoxic therapy.
Pfeiffer P; Cold S; Bertelsen K; Panduro J; Sandberg E; Rose C
Gynecol Oncol; 1990 May; 37(2):230-3. PubMed ID: 2344968
[TBL] [Abstract][Full Text] [Related]
20. Phase II evaluation of teniposide (VM-26) in metastatic breast carcinoma. A Southeastern Cancer Study Group trial.
Cox EB; Vogel CL; Carpenter JT; Raney M
Invest New Drugs; 1988 Apr; 6(1):37-9. PubMed ID: 3410666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
